UK launches Life Sciences Sector Plan amid mixed sector reactions

The UK’s new Life Sciences Sector Plan sets out six flagship actions to accelerate research, streamline regulation, and strengthen manufacturing. While welcomed as a step forward for innovation and economic growth, experts highlight that its success will depend on effective implementation and addressing challenges in pricing and patient access.

Building on its 10‑Year Health Plan, the UK government has unveiled a new Life Sciences Sector Plan designed to strengthen the nation’s position as a global leader in health innovation. Announced on July 16, 2025 and part of the government’s flagship Industrial Strategy, the plan sets out a roadmap for supporting life sciences research, scaling manufacturing capacity, and accelerating access to cutting‑edge therapies across the NHS.

Framed as a, “ten-year mission to harness British science and innovation to deliver long-term economic growth and a stronger, prevention-focused NHS,” the strategy promises over £2 billion in government funding, alongside contributions from UK Research and Innovation (UKRI) and the National Institute for Health and Care Research (NIHR). These measures are designed to address structural challenges in the UK’s life sciences sector, from regulatory delays and fragmented data systems to barriers in scaling homegrown innovation.

Six headline actions to drive transformation

The plan outlines six priority actions under three core pillars: enabling world-class R&D; making the UK an outstanding place to start, grow and invest; and driving health innovation and NHS reform.

1. A £600 million Health Data Research Service (HDRS): This initiative will create a secure, AI-ready platform integrating genomic, diagnostic, and clinical data at population scale. The HDRS is expected to transform NHS and healthcare data into a magnet for global clinical trials and AI investment.
2. Reducing clinical trial set-up times: Building on the O’Shaughnessy review, the government aims to cut trial initiation timelines to under 150 days. The goal is to double commercial trial participation by 2026 and again by 2029, making the UK a more competitive location for global R&D investment.
3. A £520 million Life Sciences Innovative Manufacturing Fund (LSIMF): This funding will support investments in advanced manufacturing, strengthening the UK’s sovereign capabilities and creating high-value jobs nationwide.
4. Making regulation and market access more efficient: The Medicines and Healthcare products Regulatory Agency (MHRA) will adopt a faster, more agile approach, working with NICE on joint advice and parallel assessments to speed up patient access to innovation.
5. Low-friction procurement pathways: The introduction of an NHS “Innovator Passport” aims to simplify adoption of new medical technologies, reducing duplication and variation across local systems.
6. Strategic partnerships with life science organizations: The government will establish at least one major strategic partnership annually with leading life sciences companies and provide dedicated support for high-potential UK firms to scale and remain headquartered in the UK.

In addition, the plan reinforces the UK’s ambition to lead in genomics and longitudinal health research. Backed by over £650 million in funding, Genomics England will expand its database to more than 500,000 genomes, building on the landmark 100,000 Genomes Project and the NHS Genomic Medicine Service. A new Adult Population Genomics Programme will sequence an additional 150,000 genomes, supporting the integration of genomics into routine preventative care.

Similarly, Our Future Health—set to become the largest longitudinal health research cohort globally—will grow to five million participants by 2030. With linked primary and secondary care data, genomic insights, and biobanked samples, this initiative aims to enable early detection of disease and support commercial trials involving 50,000 participants annually. Together with UK Biobank’s expanded multiomic data analysis, these initiatives position the UK as a leader in genomics-enabled prevention and diagnostics.

Positive reactions from the life sciences community

The Life Sciences Sector Plan has been broadly welcomed by leaders across the research and innovation community, who see it as a significant step toward supporting UK life sciences growth and improving patient outcomes. Darius Hughes, UK General Manager for Moderna, described it as a plan that, “gets the fundamentals right—from smarter regulation to investing in talent and unlocking the potential of health data.” Dr Sam Roberts, Chief Executive of National Institute for Health and Care Excellence (NICE), highlighted its collaborative vision, saying it, “establishes a clear vision for how NICE, the NHS, and industry can collaborate to truly transform people’s lives through better, more equitable access to innovation.”

Others emphasized the importance of strong governance and regulatory agility. Professor Andrew Morris, President of the Academy of Medical Sciences, pointed to the plan’s, “actionable commitments that can drive economic growth, improve the UK’s standing on a world stage and transform health equity.” Lawrence Tallon, Chief Executive of the MHRA, noted the regulator’s central role in delivering the plan’s vision to, “support innovation, protect public health, and make the UK a global destination for innovators.” Highlighting alignment with wider healthcare trends, Dr Wahbi El-Bouri, University of Liverpool, welcomed, “a clear shift toward prioritizing prevention in healthcare,” describing this as “incredibly important in getting people to live healthier lives as they age,” and reducing pressure on health and social care systems. He also noted that investment in wearable technologies could play a vital role by generating real-time data from individuals who may not otherwise engage with NHS services.

Concerns over implementation and pricing

Despite general support, some have cautioned that its success will depend on tackling systemic issues around pricing and adoption. Richard Torbett, Chief Executive of the ABPI, warned that, “the solutions proposed are necessary and important, but they are not enough to turn around the UK’s decline.” He added that, “the UK must address the core issue holding back the life sciences sector, the long-term disinvestment in innovative medicines that is increasingly preventing NHS patients from accessing medications available in other countries.” Sharon Todd, CEO of the Society of Chemical Industry (SCI), echoed these concerns, saying that, “by failing to address the way in which the NHS pays for medicines, the Government is putting its whole strategy at risk.” She warned that without agreement on drug pricing, “the UK’s life science sector, already struggling to remain globally competitive, will have fewer reasons to invest and innovate here.”

Others highlighted the need to focus on uptake and operational delivery. Professor Penny Ward, King’s College London, noted that, “the UK population has long been denied access to innovative medicines which are widely available in other countries,” and suggested the government consider not only enhancing innovation but also, “stimulating uptake of medicines and devices approved by the MHRA into practice.” David Seymour, Health Data Research UK, cautioned against “planning blight,” warning that, “the focus on designing the future system stops us from improving the performance of the current system.” He emphasized that, “the most radical thing we can do is get the basics right,” by maximizing the value of existing data assets like Clinical Practice Research Datalink (CPRD), UK Biobank, Genomics England and Our Future Health.